Recommended cognitive outcomes in preclinical Alzheimer's disease

Consensus statement from the European Prevention of Alzheimer's Dementia project

Karen Ritchie, Michael Ropacki, Bruce Albala, John Harrison, Jeffrey Kaye, Joel Kramer, Christopher Randolph, Craig W. Ritchie

Research output: Contribution to journalShort survey

27 Citations (Scopus)

Abstract

The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross-cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)186-195
Number of pages10
JournalAlzheimer's and Dementia
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Consensus
Alzheimer Disease
Dementia
Psychometrics
Neuroimaging
Biomarkers
Outcome Assessment (Health Care)
Guidelines
Research
Pharmaceutical Preparations
Population

Keywords

  • Alzheimer's disease
  • Cognition
  • Neuropsychology
  • Preclinical

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Recommended cognitive outcomes in preclinical Alzheimer's disease : Consensus statement from the European Prevention of Alzheimer's Dementia project. / Ritchie, Karen; Ropacki, Michael; Albala, Bruce; Harrison, John; Kaye, Jeffrey; Kramer, Joel; Randolph, Christopher; Ritchie, Craig W.

In: Alzheimer's and Dementia, Vol. 13, No. 2, 01.02.2017, p. 186-195.

Research output: Contribution to journalShort survey

Ritchie, Karen ; Ropacki, Michael ; Albala, Bruce ; Harrison, John ; Kaye, Jeffrey ; Kramer, Joel ; Randolph, Christopher ; Ritchie, Craig W. / Recommended cognitive outcomes in preclinical Alzheimer's disease : Consensus statement from the European Prevention of Alzheimer's Dementia project. In: Alzheimer's and Dementia. 2017 ; Vol. 13, No. 2. pp. 186-195.
@article{730bb975464d4347831456470c255eff,
title = "Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project",
abstract = "The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross-cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.",
keywords = "Alzheimer's disease, Cognition, Neuropsychology, Preclinical",
author = "Karen Ritchie and Michael Ropacki and Bruce Albala and John Harrison and Jeffrey Kaye and Joel Kramer and Christopher Randolph and Ritchie, {Craig W.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.jalz.2016.07.154",
language = "English (US)",
volume = "13",
pages = "186--195",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Recommended cognitive outcomes in preclinical Alzheimer's disease

T2 - Consensus statement from the European Prevention of Alzheimer's Dementia project

AU - Ritchie, Karen

AU - Ropacki, Michael

AU - Albala, Bruce

AU - Harrison, John

AU - Kaye, Jeffrey

AU - Kramer, Joel

AU - Randolph, Christopher

AU - Ritchie, Craig W.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross-cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.

AB - The Horizon 2020/IMI European Prevention of Alzheimer's Dementia (EPAD) project will undertake large-scale proof-of-concept trials in predementia Alzheimer's disease (AD). Within EPAD, the monitoring of cognitive trajectories in the preclinical period will constitute a central outcome measure; however, there are currently no clear guidelines as to how this should be achieved as most measures have been developed for the period around dementia diagnosis. The EPAD Scientific Advisory Group for Clinical and Cognitive Outcomes identified appropriate cognitive measures based on a literature search covering both cognitive correlates of preclinical brain changes from imaging studies and cognitive changes observed over time in nondementia population cohorts developing incident dementia. These measures were evaluated according to the following criteria: validity, coherence with biomarker changes, psychometric properties, cross-cultural suitability, availability of alternative forms, and normative data limited practice effects. The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer's disease.

KW - Alzheimer's disease

KW - Cognition

KW - Neuropsychology

KW - Preclinical

UR - http://www.scopus.com/inward/record.url?scp=85006295188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006295188&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.07.154

DO - 10.1016/j.jalz.2016.07.154

M3 - Short survey

VL - 13

SP - 186

EP - 195

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -